Sorrento Therapeutics has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncology agents for the treatment of metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and other cancers. The combined company would include potential products with Phase II data for multiple solid tumor indications, as well as two synergistic drug discovery and development platforms.   IGDRASOL’s lead compound, Cynviloq, is a next-generation injectable...